Findings

What do systematic reviews say?

5 questions · 5 findings · 2 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 20%Low 2 · 40%Moderate 2 · 40%High 0 · 0%

Adverse events · Patients with active mild to moderate ulcerative colitis

Once daily dosing showed no clear difference in adverse events compared with conventional dosing (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.02 [0.89, 1.18]
4 studies · 1586 participants
Moderate

Serious adverse events · Patients with active mild to moderate ulcerative colitis

Once daily dosing showed no clear difference in serious adverse events compared with conventional dosing (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.34 [0.68, 2.66]
4 studies · 1586 participants
Low

Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis

Once daily dosing showed no clear difference in withdrawal due to adverse events compared with conventional dosing (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.89 [0.54, 1.49]
5 studies · 1757 participants
Low

Serious adverse events · Patients with quiescent ulcerative colitis

Once‐daily dosing showed no clear difference in serious adverse events compared with conventional dosing (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.2 [0.77, 1.87]
7 studies · 3196 participants
Moderate

Withdrawals due to adverse events · Patients with quiescent ulcerative colitis

It is very uncertain whether once‐daily dosing changes withdrawal due to adverse events compared with conventional dosing (very low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.18 [0.74, 1.89]
8 studies · 4340 participants
Very low